AI Accelerates Clinical Trial Data Review and Quality Management

Artificial intelligence is being applied to clinical trial data to help sponsors and research teams identify risks, resolve data issues, and focus expert attention earlier in the study lifecycle. Industry analyses show that about 80 % of trials still miss enrollment targets, and AI‑driven platforms aim to cut these delays by organizing and prioritising large, multi‑source datasets.

Digital solutions such as Qlarix’s Risk‑Based Quality Management system complement AI by linking critical‑to‑quality factors, supporting protocol optimisation, participant selection, enrollment forecasting and detection of unusual data patterns. Together, these tools seek to improve operational efficiency, regulatory compliance and overall speed of bringing new therapies to market.